



California COVID-19 Testing Task Force Elected Official Briefing

June 17, 2020

Agenda



Introductions and logistics



Objectives



Approach



Progress



Next steps



Questions

Logistics



- **Participation by invitation only** – please send participation requests to testing.taskforce@state.ca.gov
- All of this is to facilitate a **trusted, open dialogue** in a highly fluid situation
- **A newsletter** will follow this meeting and can be used to share with/update others in your community

Introductions



Today's speakers

- **Dr. Charity Dean**, Assistant Director, California Department of Public Health
- **Paul Markovich**, President and CEO, Blue Shield of California
- **Dr. Christina Kong**, Vice Chair and Medical Director of Pathology & Clinical Lab, Stanford University

List of Task Force leaders provided on Task Force website at testing.covid19.ca.gov


Roles in this public-private partnership

- Appropriate state officials **always** make decisions
- Individuals from the private sector are providing important support at a critical juncture and **do not** make decisions

Two types of COVID-19 tests mentioned in these materials



PCR (molecular diagnostic) and Antigen tests



Serological tests

Detection of...

Virus

Antibodies

Common sample type

Nose nasal or throat swab

Blood/plasma

Key considerations

PCR is gold standard for diagnostic testing

Do not diagnose infection, but can be useful for antibody detection

Task Force goals and approach

Our goals

Increase total number of tests

24-hour turnaround

90% accuracy

Equitable and convenient access



Our approach



Access: Establish statewide collection sites for equitable access



Test processing: Maximize throughput and turnaround time of labs



Statewide distribution: Establish a smart distribution of scarce supplies



Facilitate innovation: Provide recommendations on new, promising tests



Data and analytics: Track and report results




Community-driven workforce needs: Maximize using members of the community for the work

Reaching our goals will require taking a range of actions

Current and expected number of COVID-19 tests in California

Tests/day (PCR Tests)




Actions to increase test volumes:



- Increase capacity for existing labs to process tests
- Increase number of specimens collected for processing
- Assess and deploy new tests (e.g., point of care, serology)

Task Force is optimizing end-to-end testing workflows



CA Task Force Team





The network of testing sites is being expanded to provide equitable access across the state

Current as of 05/17

Criteria for recommendation of additional sites:



- Ensure access to testing in underserved communities
- Ensure a collection site within approx. **30 min** driving time in urban areas and within approx. **60 min** in rural areas
- Ensure there is sufficient capacity to meet state requirements for reopening (**1.5 tests per 1,000 people**)

Network of testing active sites in California

OptumServe sites

82

Verily sites

29¹

Other community sites (including drive-throughs, clinics, urgent care centers, and other sites)

340+

1. 24 fixed, 5 mobile rotating between rural locations



The Task Force has launched an integrated directory of testing sites

Finding a Testing Site

Search by address, city, county, or ZIP code

10
0 mi — 100 mi

To find a COVID-19 testing site near you, try one of these options.

- Choose Current Location
- Search by Address, City or Zip Code
- Click on the Map

Contact your health plan for additional testing options.
For more information about preventing the spread of COVID-19, visit covid19.ca.gov.

Map Legend

- OptumServe Sites
- Verily Sites
- GISCorps Community Sites

CALIFORNIA ALL
Your Actions Save Lives
covid19.ca.gov

- ✓ Locations and working hours for all Verily, OptumServe, and other community testing sites
- ✓ Search by location (address, zip, county)
- ✓ Links and phone numbers to schedule appointments



The Task Force is working to secure scarce supplies for sample collection and test processing



Current as of 06/15



Sample collection supplies

- The Task Force confirmed and operationalized **supply distribution model** in partnership with RDMHSs and MHOACs
- Distribution completed for ~**2.4M swabs and 1.5M units of viral transport media**
- **3M+ swabs** expected to be delivered by end of June
- **All 59 operating areas** have received swabs to date



Test processing supplies


- The Task Force is in **active collaboration with all major manufacturers** to resolve supply shortages
- The state purchased **1.5M Abbott serology kits** and **250k testing kits for Abbott m2000 machines**



We are tracking tests/day daily

Current as of 06/15

Total testing volume in California, tests/day




We are also examining new tests and alternative methods

Assessment approach



Serology tests *(details follow)*

Technical assessment that includes a comprehensive set of performance metrics and follows a systematic multi-step approach



Rapid point of care tests

Focus on symptomatic cases in ER, ICU, or congregate settings, vulnerable populations, and first responders



Specimen pooling

Assessment focused on feasibility and identification of low prevalence areas where pooling may be beneficial

The Task Force is monitoring new technologies that promise to increase access to testing



Infectious Disease Society of America (IDSA) Guidelines on the Diagnosis of COVID-19:

Suggests mid-turbinate (MT) or nasal swabs are acceptable alternatives to nasopharyngeal swabs in symptomatic individuals

Suggests that nasal and MT swabs may be collected by *either* patients (at home self-collection with appropriate training) or healthcare providers

Saliva collection: Insufficient data. Given significant interest, the panel anticipates additional studies to better inform on test performance

Tests with *at home self collection kits* now available: *Current as of May 17, 2020*

- Rutgers' Clinical Genomics Lab – Saliva
- Pixel by LabCore – Nasal swab
- Fulgent Therapeutics, LLC* – Nasal swab
- Assurance Scientific Laboratories* – Nasal swab

* Everlywell supplies COVID-19 nasal swab kit



COVID Tracker



COVID-19 Genomic Sequencing and Analysis for California Public Health

Chan Zuckerberg Biohub, in partnership with the Chan Zuckerberg Initiative, CDPH and California local health jurisdictions, is launching no-cost genome sequencing to support the pandemic response:

Specimen Type – Extracted RNA or swab in RNA Shield™ (Zymo Research)

Sequencing: Genome sequence data TAT within 10 business days of receipt; will support more rapid (<5 days) TAT for urgent sequencing needs

Analysis: Make data actionable for public health surveillance and response

Data Portal: A portal for visualization & investigation of data. LHJs may overlay epi and demographic data to better inform transmission chains and contact tracing

Training: CZ Biohub is committed to supporting local health jurisdiction capacity building

Step 1: Email covidtracker@czbiohub.org to express interest

Transition plan

State TTF



- Statewide testing guidance
- Oversight of local testing solutions and efforts
- Data consolidation, monitoring and state-level reporting
- Targeted state-led or state-funded solutions
- Maintain relationships and contracts with statewide partners



County-led testing efforts




- Design and setup of testing solutions for various population cohorts (including for contact tracing)
- Expansion and maintenance of testing sites to provide equitable access to testing
- Contracting with labs, site operators, and other partners
- Data sharing and reporting



Private partners

- Ongoing support and thought partnership for the TTF leadership
- Participation in working sessions on specific topics and approaches



Transition to be completed by 6/30

What we hope you take away from this session

- We have developed a comprehensive but highly manual picture of testing in CA
- Picture is dynamic, changing every day
- Task Force is working hard to help:
 - Optimize distribution of testing supplies and equipment where needed
 - Recommend when new tests should be put into widespread use
 - Propose resources needed to expand testing capacity
 - Ensure equitable and appropriate statewide access to testing
- Efforts are gaining traction as we have moved from ~2,000 tests per day when we started, to going past our 25,000 tests per day goal by end of April and currently to more than ~75K per day as our latest peak daily volume (6/11)
- We have a path to further increase tests per day and plenty of work left to do to achieve it

Next Steps



- Visit testing.covid19.ca.gov to learn more
- Please reach out to testing.taskforce@state.ca.gov if you have any questions about the Task Force efforts